- $11.72m
- $11.67m
- $41.71m
Brief: Biofrontera Inc Enters Into Agreements To Purchase Options Of Biofrontera AG
Brief: Biofrontera Inc Names Fred Leffler As Chief Financial Officer
Brief: Biofrontera Adopts Limited Duration Shareholder Rights Plan
Brief: Biofrontera Announces Prelim Product Revenues For Q3 2022
Brief: Biofrontera Names Gerard Digirolamo As National Sales Director
Brief: Biofrontera Reports Q2 Revenue Of $4.5 Mln, Down 24%
Brief: Biofrontera Inc. Announces Patent In Australia
Brief: Biofrontera Announces Preliminary Product Revenues For The Second Quarter Of 2022
Brief: Biofrontera Inc Files Prospectus Relates To Offering And Resale From Time To Time By Selling Stockholder Of Up To 9.7 Million Shares Of Common Stock
Brief: Biofrontera Inc Announces Pricing Of $9.4 Million Private Placement
Brief: Biofrontera Reports Q1 Revenue Rose 106%
Biofrontera soars after FDA approves Germany lab for testing skin treatment
NASDAQ RESUMED AT 10:58 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:53 AM
NASDAQ RESUMED AT 10:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:42 AM
NASDAQ RESUMED AT 10:41 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:31 AM
NASDAQ RESUMED AT 10:30 AM